About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ARWR · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 10, 2026Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Pri…
NCT07221344 · Alzheimer Disease, Tauopathies
ARO-MAPT-SC, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1/2Recruiting160Jun 2027Registry ↗
Oct 30, 2026A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
NCT06700538 · Obesity
ARO-INHBE, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1/2Active, not recruiting
was recruiting
190Oct 15, 2027Registry ↗
Oct 26, 2026Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
NCT07473843 · Homozygous Familial Hypercholesterolemia
Zodasiran
ARWR
Arrowhead Pharmaceuticals
Phase 3Recruiting10Jul 2028Registry ↗
Oct 13, 2026Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
NCT07223658 · Hyperlipidemia; Mixed
ARO-DIMERPA, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1/2Recruiting78Jul 2027Registry ↗
Oct 9, 2026Study of Plozasiran in Adults With Severe Hypertriglyceridemia
NCT06347016 · Severe Hypertriglyceridemia
Plozasiran Injection, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 3Completed311Jun 17, 2026Registry ↗
Oct 8, 2026Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003 · Severe Hypertriglyceridemia
Plozasiran Injection, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 3Completed446Jun 12, 2026Registry ↗
Oct 6, 2026A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Assoc…
NCT07859813 · Metabolic Dysfunction-Associated Steatohepatitis
ARO-INHBE, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 2Not yet recruiting252Oct 2029Registry ↗
Oct 1, 2026Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
NCT07241546 · Asthma
ARO-RAGE, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 2Recruiting36Dec 2027Registry ↗
Oct 1, 2026Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790 · Hypertriglyceridemia
Plozasiran Injection
ARWR
Arrowhead Pharmaceuticals
Phase 3Active, not recruiting710Jul 2028Registry ↗
Sep 25, 2026Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
NCT06347133 · Hypertriglyceridemia
Plozasiran Injection, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 3Completed1,456Jun 1, 2026Registry ↗
Sep 21, 2026Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770 · Severe Hypertriglyceridemia
Plozasiran, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 3Recruiting288Mar 2029Registry ↗
Sep 15, 2026A First-In-Human Study of ARO-033 in Adult Participants
NCT07662096 · Age-related Macular Degeneration
ARO-033, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1Recruiting84Jul 1, 2028Registry ↗
Sep 14, 2026Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
NCT05292950 · Asthma, Chronic Obstructive Pulmonary Disease
ARO-MUC5AC, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1/2Terminated78Nov 12, 2024Registry ↗
Aug 12, 2026A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholest…
NCT07037771 · Homozygous Familial Hypercholesterolemia
zodasiran Injection, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 3Active, not recruiting70Aug 20, 2027Registry ↗
Aug 5, 2026Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulm…
NCT05537025 · Idiopathic Pulmonary Fibrosis
ARO-MMP7 Inhalation Solution, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1/2Completed105Sep 5, 2025Registry ↗
Jul 8, 2026A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
NCT06937203 · Obesity, Diabetes Mellitus, Type 2
ARO-ALK7, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1/2Recruiting150Feb 2027Registry ↗
Jun 29, 2026Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
NCT06672445 · Spinocerebellar Ataxia Type 2
ARO-ATXN2 Injection, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1Active, not recruiting39Dec 2026Registry ↗
Jun 12, 2026Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
NCT05217667 · Homozygous Familial Hypercholesterolemia
ARO-ANG 3 Injection
ARWR
Arrowhead Pharmaceuticals
Phase 2Terminated18May 2, 2023Registry ↗
Jun 5, 2026Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
NCT05089084 · Familial Chylomicronemia
Plozasiran, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 3Completed75Apr 29, 2024Registry ↗
May 22, 2026Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
NCT05083364 · C3 Glomerulopathy, IgA Nephropathy
ARO-C3, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1/2Completed62Sep 10, 2025Registry ↗
May 20, 2026Study of ARO-CFB in Adult Healthy Volunteers
NCT06209177 · IgA Nephropathy
ARO-CFB, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1Completed49Mar 31, 2025Registry ↗
May 12, 2026Study of ARO-APOC3 in Adults With Dyslipidemia
NCT05413135 · Dyslipidemias
ARO-APOC3
ARWR
Arrowhead Pharmaceuticals
Phase 2Completed418Sep 22, 2025Registry ↗
Apr 14, 2026Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
NCT04998201 · Mixed Dyslipidemia
ARO-APOC3, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 2Completed353Feb 10, 2023Registry ↗
Apr 9, 2026Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease
NCT05276570 · Asthma
ARO-RAGE, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1/2Completed127Apr 16, 2025Registry ↗
Mar 24, 2026Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
NCT04720534 · Severe Hypertriglyceridemia
ARO-APOC3, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 2Completed229Mar 9, 2023Registry ↗
Mar 3, 2026Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in…
NCT06796426 · Familial Chylomicronemia, High Risk Severe Hypertriglycerid…
Plozasiran
ARWR
Arrowhead Pharmaceuticals
—Available——Registry ↗
Jan 13, 2026Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chron…
NCT02738008 · Hepatitis B
ARC-520 Injection, entecavir
ARWR
Arrowhead Pharmaceuticals
Phase 2Terminated12Dec 2016Registry ↗
Jan 13, 2026A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic He…
NCT02604212 · Hepatitis B
ARC-520, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 2Terminated32Dec 2016Registry ↗
Jan 13, 2026A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic He…
NCT02604199 · Hepatitis B
ARC-520 Injection, placebo
ARWR
Arrowhead Pharmaceuticals
Phase 2Terminated58Jan 2017Registry ↗
Jan 13, 2026Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B V…
NCT02577029 · Hepatitis B, Hepatitis D
ARC-520, entecavir
ARWR
Arrowhead Pharmaceuticals
Phase 2Terminated79Dec 2016Registry ↗
Jan 13, 2026A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers
NCT02535416 · Healthy
ARC-520, cetirizine
ARWR
Arrowhead Pharmaceuticals
Phase 1Completed40Aug 2016Registry ↗
Jan 13, 2026A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Redu…
NCT02065336 · Hepatitis B, Chronic
ARC-520, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 2Terminated58Jan 2017Registry ↗
Jan 12, 2026A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
NCT02797522 · Hepatitis B
ARC-521 Injection, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1Terminated47Nov 2016Registry ↗
Jan 12, 2026A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (…
NCT02363946 · Alpha-1 Antitrypsin Deficiency
ARC-AAT Injection, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1Terminated65Nov 2016Registry ↗
Dec 26, 2025Study of ARC-520 in Patient With Chronic Hepatitis B Virus
NCT02349126 · Chronic Hepatitis B
ARC-520 Injection
ARWR
Arrowhead Pharmaceuticals
Phase 2Withdrawn0Dec 2015Registry ↗
Dec 26, 2025Safety and Tolerability Study of ARC-520 in Healthy Volunteers
NCT01872065 · Healthy
ARC-520, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1Completed54Sep 2014Registry ↗
Dec 24, 2025Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial…
NCT03783377 · Hypertriglyceridemia, Familial Chylomicronemia
ARO-APOC3, sterile normal saline (0.9% NaCl)
ARWR
Arrowhead Pharmaceuticals
Phase 1Completed112Feb 11, 2021Registry ↗
Dec 24, 2025Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
NCT03747224 · Dyslipidemias, Familial Hypercholesterolemia
ARO-ANG3, sterile normal saline (0.9% NaCl)
ARWR
Arrowhead Pharmaceuticals
Phase 1Completed93May 17, 2021Registry ↗
Dec 24, 2025Study of ARO-AAT in Normal Adult Volunteers
NCT03362242 · Alpha 1-Antitrypsin Deficiency
ARO-AAT Injection, Sterile Normal Saline (0.9% NaCl)
ARWR
Arrowhead Pharmaceuticals
Phase 1Completed45Oct 23, 2018Registry ↗
Dec 18, 2025Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitr…
NCT02900183 · Alpha-1 Antitrypsin Deficiency
ARC-AAT Injection
ARWR
Arrowhead Pharmaceuticals
Phase 2Withdrawn0Nov 2016Registry ↗
Dec 17, 2025Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis
NCT04375514 · Cystic Fibrosis, Pulmonary
ARO-ENaC, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1/2Terminated43May 9, 2021Registry ↗
Dec 3, 2025Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
NCT04832971 · Mixed Dyslipidemia
ARO-ANG3, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 2Completed204Aug 30, 2022Registry ↗
Nov 4, 2025Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
NCT03945292 · Alpha 1-Antitrypsin Deficiency
Fazisiran Injection, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 2Completed40Nov 8, 2021Registry ↗
Nov 3, 2025Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatiti…
NCT02452528 · Chronic Hepatitis B
ARC-520, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 2Terminated4Dec 2016Registry ↗
Oct 22, 2025Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)
NCT03365947 · Hepatitis B
ARO-HBV, Sterile Normal Saline (0.9% NaCl)
ARWR
Arrowhead Pharmaceuticals
Phase 1/2Completed114Apr 23, 2020Registry ↗
Oct 15, 2025Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated L…
NCT03946449 · Alpha 1-Antitrypsin Deficiency
ARO-AAT
ARWR
Arrowhead Pharmaceuticals
Phase 2Completed16Apr 28, 2022Registry ↗
Oct 9, 2025Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT04169711 · Clear Cell Renal Cell Carcinoma
ARO-HIF2
ARWR
Arrowhead Pharmaceuticals
Phase 1Completed26Jan 24, 2022Registry ↗
Oct 3, 2025Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Su…
NCT04202354 · Non-alcoholic Steatohepatitis
ARO-HSD Injection, sterile normal saline (0.9% NaCl)
ARWR
Arrowhead Pharmaceuticals
Phase 1/2Completed50Sep 3, 2021Registry ↗
Apr 17, 2024Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT05949294 · Amyotrophic Lateral Sclerosis
ARO-SOD1 Injection
ARWR
Arrowhead Pharmaceuticals
Phase 1Withdrawn0Mar 2025Registry ↗
Mar 29, 2024Study of ARO-RAGE in Healthy Subjects
NCT05533294 · Asthma
ARO-RAGE Injection, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 1Completed43Feb 8, 2024Registry ↗

50 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:51 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances